Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.51 |
| ▸ | CACNA1H | O95180 | 10/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.46 |
| ▸ | TUBB | P07437 | 1/20 | 0.46 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.46 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.46 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.46 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.46 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.46 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.46 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13114464 | 0.88 | HPGD (0.55) | MAPTHPGDTSHRCHRNA7CACNA1H | |
| SCHEMBL28839373 | 0.85 | CHRNA7 (0.49) | CHRNA7CACNA1HLMNATHRBFAAH | |
| SCHEMBL17653861 | 0.84 | CACNA1H (0.46) | CHRNA7CACNA1HFAAHTUBB4ATUBB | |
| SCHEMBL5094204 | 0.83 | KDM4E (0.58) | MAPTHPGDTSHRCHRNA7CACNA1H | |
| SCHEMBL23718212 | 0.82 | TUBB4A (0.50) | MAPTHPGDTSHRALDH1A1GAA | |
| SCHEMBL8990479 | 0.81 | CACNA1H (0.50) | MAPTCHRNA7CACNA1HLMNAFAAH | |
| SCHEMBL22255705 | 0.80 | CHRNA7 (0.45) | CHRNA7CACNA1HLMNATHRBFAAH | |
| SCHEMBL21620954 | 0.78 | ALDH1A1 (0.61) | MAPTHPGDTSHRALDH1A1GAA | |
| SCHEMBL20424546 | 0.77 | MAPT (0.42) | MAPTHPGDTSHRCACNA1HALDH1A1 | |
| SCHEMBL21550065 | 0.76 | TSHR (0.48) | MAPTHPGDTSHRALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110225911-B | Oxadiazolone transient receptor potential channel inhibitors | 豪夫迈·罗氏有限公司 | 2022-04-05 | — | — | CN | disclosed |
| EP-3544979-B1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | disclosed |
| EP-3544979-B1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | disclosed |
| US-10913742-B2 | Oxadiazolones as transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10913742-B2 | Oxadiazolones as transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| EP-3544979-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2019-10-02 | — | — | EP | disclosed |
| US-20190284189-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-20190284189-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| WO-2018096159-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018096159-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913742-B2 | Oxadiazolones as transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | MAPT 3057/4885HPGD 346/4885TSHR 2531/4885 |
| US-20190284189-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | MAPT 3057/4885HPGD 346/4885TSHR 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.